![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Uric acid in heart failure: a biomarker or therapeutic target?
1University of South Florida, Tampa, FL, USA.
Insights
Uric acid (UA) is a key prognostic biomarker in heart failure (HF), but its role in disease progression is unclear. This review explores UA
Area of Science:
- Cardiology
- Biomarkers
- Renal Medicine
Background:
- Heart failure (HF) requires cost-effective prognostic biomarkers.
- Uric acid (UA) is recognized as an independent marker for adverse prognosis in various HF stages.
- The precise role of UA in HF pathogenesis versus being a mere marker remains undetermined.
Purpose of the Study:
- To review the association between uric acid and heart failure prognosis.
- To examine mechanisms contributing to elevated uric acid levels in HF patients.
- To discuss novel therapeutic strategies targeting uric acid reduction in HF.
Main Methods:
- Literature review of existing studies on uric acid and heart failure.
- Analysis of pathophysiological mechanisms linking uric acid to HF.
- Synthesis of evidence regarding UA-lowering treatments in HF.
Main Results:
- Elevated uric acid levels in HF are linked to increased production (e.g., oxidative stress) and decreased renal excretion (e.g., cardio-renal syndrome).
- Pioneer studies suggest potential benefits of UA-lowering agents, but clinical evidence remains conflicting.
- UA's dual role as a marker and potential contributor to HF progression requires further investigation.
Conclusions:
- Uric acid is a significant prognostic marker in heart failure.
- Understanding the mechanisms of elevated UA in HF is crucial for developing targeted therapies.
- Further research is needed to confirm the clinical benefits of reducing uric acid levels in heart failure management.
Abstract:
There is a need for a cost-effective prognostic biomarker in heart failure (HF). Substantial evidence suggests that uric acid (UA) is an independent marker for adverse prognosis in acute and chronic HF of varying severity. Whether UA is a merely a marker of poor prognosis or is an active participant in disease pathogenesis is currently unknown. In the setting of HF, at least two different processes can be responsible for increased UA: increased production, which may result from oxidative stress, and decreased excretion due to renal insufficiency, which can be a consequence of cardio-renal syndrome, renal congestion, or comorbidities. While pioneer studies have raised the possibility of preventing HF through the use of UA lowering agents, namely xanthine oxidase inhibitors and uricosurics, the literature is still conflicting on whether the reduction in UA will result in a measurable clinical benefit. In this review, we examine the evidence relating UA to HF prognosis, the mechanisms that contribute to increased UA levels in HF, and future novel treatments aimed at reducing UA levels.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:22Heart Failure Drugs: Diuretics
01:29Heart Failure II: Pathophysiology
01:22Heart Failure VI: Adjunct Therapies